Gilead Sciences, Inc. (GILD) SEC filings

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value

$168.08+0.13 (+0.08%)

Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%

SEC filings

40 of Gilead Sciences's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Oct 30, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 20, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	May 4, 2026	SEC EDGAR
Current report	8-K	Apr 28, 2026	Apr 28, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 30, 2026	Mar 20, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 24, 2026	SEC EDGAR
Current report	8-K	Feb 22, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Feb 10, 2026	Feb 10, 2026	SEC EDGAR
Current report	8-K	Nov 15, 2025	Nov 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 7, 2025	SEC EDGAR
Current report	8-K	Oct 30, 2025	Oct 30, 2025	SEC EDGAR
Current report	8-K	Oct 6, 2025	Oct 6, 2025	SEC EDGAR
Current report	8-K	Aug 10, 2025	Aug 14, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jul 30, 2025	Aug 4, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 8, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	Apr 24, 2025	Apr 24, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 7, 2025	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 9, 2025	Mar 12, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 28, 2025	SEC EDGAR
Current report	8-K	Feb 11, 2025	Feb 11, 2025	SEC EDGAR
Current report	8-K	Nov 20, 2024	Nov 20, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 17, 2024	Jul 17, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 9, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	Apr 25, 2024	Apr 25, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 8, 2024	Mar 28, 2024	SEC EDGAR
Current report	8-K	Mar 22, 2024	Mar 22, 2024	SEC EDGAR
Current report	8-K	Mar 10, 2024	Mar 14, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Gilead Sciences's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jan 28, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GILD.

Compare: GILD vs AMGN · GILD vs BIIB · GILD vs GSK · GILD vs VTRS · GILD vs TEVA

Revenue growth6.5% · median 3.3%

Gross margin79.9% · median 67.7%

Operating margin-7.6% · median 11.4%

Net margin-12.5% · median 5.0%

Company	Revenue	Growth
AMGN	$38.90B	+8.2%
GILD	$30.99B	+6.5%
VTRS	$14.73B	+4.3%
TEVA	$14.10B	-15.2%
BIIB	$10.30B	+2.3%
GSK	–	–

Company

Next earnings (est.): Feb 9, 2027, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 17,000
Held by institutions: 89.8%
Auditor: Ernst & Young LLP
SEC CIK: 882095

Advertisement
300 × 250

See a number that looks wrong?